Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium
Dateline City:
KENILWORTH, N.J.
Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that new and updated findings investigating the use of
KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy,
in multiple gastrointestinal cancers will be presented at this year’s
Gastrointestinal (GI) Cancers Symposium in San Francisco, Jan. 21 – 23.
Updates on pembrolizumab include data on advanced esophageal carcinoma
and new preliminary Phase 2 safety data in gastric cancer.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK GI Cancers Symposium NYSE:MRK Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Merck | Pharmaceuticals